Liminatus Pharma, Inc. (LIMN) Form 424B3 — Jun 3, 2026
Liminatus Pharma, Inc. (LIMN) filed a prospectus supplement to amend its S-1 registration, reducing the exercise price of its warrants from $0.29 to $0.18 per share. This significant cut in the strike price reflects a decline in the company's stock value, which was last reported at $0.195 per share on June 2, 2026. The offering includes 8.27 million shares of common stock, 5.54 million pre-funded warrants, and 13.81 million warrants to purchase additional shares.
Key figures
- Gross Proceeds
- 0
- Offering Price
- 0.195
- Shares Offered
- 13813000
- Warrants Offered
- 13813000
- Warrant Exercise Price
- 0.18
- Placement Agent Warrants
- 690650
- Pre Funded Warrants Offered
- 5543000
- Prior Warrant Exercise Price
- 0.29
- Last Reported Stock Price
- 0.195
- Last Reported Warrant Price
- 0.09
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.